Price T Rowe Associates Inc Replimune Group, Inc. Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
A detailed history of Price T Rowe Associates Inc transactions in Replimune Group, Inc. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 9,236,057 shares of REPL stock, worth $108 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
9,236,057
Previous 6,548,930
41.03%
Holding current value
$108 Million
Previous $53.5 Million
55.36%
% of portfolio
0.01%
Previous 0.01%
Shares
15 transactions
Others Institutions Holding REPL
# of Institutions
154Shares Held
70MCall Options Held
26.7KPut Options Held
28.6K-
Baker Bros. Advisors LP New York, NY10MShares$117 Million1.2% of portfolio
-
Redmile Group, LLC San Francisco, CA5.56MShares$65 Million3.26% of portfolio
-
Fcpm Iii Services B.V. Naarden, P74.87MShares$56.9 Million6.46% of portfolio
-
Black Rock Inc. New York, NY4.71MShares$55.1 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.12MShares$36.4 Million0.01% of portfolio
About Replimune Group, Inc.
- Ticker REPL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,306,700
- Market Cap $576M
- Description
- Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...